Pfizer's HYMPAVZI? Approved in EU for Hemophilia A and B
DataM Intelligence
Market Research & Consulting Firm. This page updates readers with industry particular reports uploaded on our website.
On 20th November 2024 PFIZER INC. gained the European Commission (EC) approval for marketing authorization for HYMPAVZI? (marstacimab) for the routine prophylaxis of bleeding episodes in patients 12 years of age and older with severe hemophilia A or hemophilia B without inhibitors.
A First-of-Its-Kind Treatment
HYMPAVZI is a significant breakthrough in hemophilia treatment . It is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the EU for both hemophilia A and B. This once-weekly subcutaneous treatment offers several advantages over traditional therapies:
Convenient Administration: HYMPAVZI can be self-administered via a pre-filled pen or syringe, reducing the need for frequent clinic visits.
Reduced Bleeding Episodes: Clinical trials have shown that HYMPAVZI significantly reduces the annualized bleeding rate (ABR) compared to standard prophylaxis.
Improved Quality of Life: By reducing the frequency of bleeding episodes and simplifying treatment regimens, HYMPAVZI can improve the quality of life for people with hemophilia.
A Commitment to Hemophilia Patients
Pfizer has a long-standing commitment to advancing hemophilia research and developing innovative treatments. With the approval of HYMPAVZI, the company continues to lead the way in improving the lives of people with hemophilia.
About Hemophilia
Hemophilia is a rare genetic bleeding disorder that affects approximately 800,000 people worldwide. It is caused by a deficiency in clotting factors, leading to excessive bleeding.